Troubled Grant Giver Can Resume

Texas lawmakers lifted a ban on a taxpayer-funded research organization to dole out grants.

Written byKerry Grens
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

WIKIMEDIA, MAKARISTOSThe taxpayer-funded Cancer Prevention and Research Institution of Texas (CPRIT) launched in 2007 to fund Texas-based cancer researchers with $3 billion in bonds. But the organization's grant-giving came to a halt last year after alleged corruption and a lack of peer review in determining how funds should be allocated. CPRIT's leadership underwent a major shake-up, and last week lawmakers gave the OK for the agency to resume grant-making operations.

“There were things that needed to be cleaned up,” Kevin Gardner, a structural biologist at the University of Texas Southwestern Medical Center in Dallas, told Nature. “As a Texan taxpayer, I'm glad they were cleaned up. As a scientist, I saw this put a serious dent in the research programs throughout the state.”

Gardner's grant from CPRIT was among the $100 million in total research funds that were frozen under the state’s moratorium. Wayne Roberts, the institute's interim executive director, told the Associated Press that his group will discuss the awarded research with recipients to make sure their projects haven't changed.

According to the AP, state prosecutors launched a criminal investigation into CPRIT after the institute allegedly funded a biotech company, Peloton Therapeutics, without fully ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • kerry grens

    Kerry served as The Scientist’s news director until 2021. Before joining The Scientist in 2013, she was a stringer for Reuters Health, the senior health and science reporter at WHYY in Philadelphia, and the health and science reporter at New Hampshire Public Radio. Kerry got her start in journalism as a AAAS Mass Media fellow at KUNC in Colorado. She has a master’s in biological sciences from Stanford University and a biology degree from Loyola University Chicago.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies